{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:23:27Z","timestamp":1792225407725,"version":"4.4.0"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011010","name":"European SocieTy for Radiotherapy and Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.radonc.2025.111330","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:43:34Z","timestamp":1765471414000},"page":"111330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4\/6, HER2, PARP, or mTOR inhibitors"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-4435","authenticated-orcid":false,"given":"Evert S.M.","family":"van Aken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5713-0963","authenticated-orcid":false,"given":"Ajeet Kumar","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-9199","authenticated-orcid":false,"given":"Sean M.","family":"O\u2019Cathail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben","family":"Borst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Barriuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Fokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Castelo-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8264-3223","authenticated-orcid":false,"given":"Anne Hansen","family":"Ree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kroeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0602-8667","authenticated-orcid":false,"given":"Ilaria","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4798-8899","authenticated-orcid":false,"given":"Antonin","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":false,"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Szutowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Liposits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-7421","authenticated-orcid":false,"given":"Marcel","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulien","family":"Boot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9269-6567","authenticated-orcid":false,"given":"Dirk De","family":"Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6632-2462","authenticated-orcid":false,"given":"George","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrie A.M.","family":"Marijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4406-7621","authenticated-orcid":false,"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7214-4818","authenticated-orcid":false,"given":"Diogo","family":"Martins-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsela","family":"Prelaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-6789","authenticated-orcid":false,"given":"Monique C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-0905","authenticated-orcid":false,"given":"Bharti","family":"Devnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111330_b0005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.radonc.2025.111330_b0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JGO.2015.001545","article-title":"Global access to radiotherapy services: have we made progress during the past decade?","volume":"2","author":"Yap","year":"2016","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0015","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMra1608986","article-title":"Recent developments in radiotherapy","volume":"377","author":"Citrin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111330_b0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","article-title":"Radiotherapy toxicity","volume":"5","author":"De Ruysscher","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.radonc.2025.111330_b0025","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2025.111330_b0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0035","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/cncr.22555","article-title":"A review of hypofractionated palliative radiotherapy","volume":"109","author":"Lutz","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0040","first-page":"93","article-title":"Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: dutch survey on current practice, knowledge and challenges","volume":"33","author":"van Aken","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110910","article-title":"ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy","volume":"208","author":"van Aken","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0050","first-page":"e1470","article-title":"Unexpected toxicity of CDK4\/6 inhibitor palbociclib and radiotherapy","volume":"5","author":"van Aken","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.radonc.2025.111330_b0055","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer","volume":"27","author":"de Haan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0060","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/annonc\/mdv139","article-title":"Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients","volume":"26","author":"Hecht","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0065","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1200\/JCO.2013.49.3528","article-title":"Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy","volume":"32","author":"Harding","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijrobp.2013.05.012","article-title":"Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT)","volume":"87","author":"Barney","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0075","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2007.15.8451","article-title":"Bowel perforation after radiotherapy in a patient receiving sorafenib","volume":"26","author":"Peters","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194780","article-title":"Continued versus interrupted targeted therapy during metastasis-directed stereotactic radiotherapy: a retrospective multi-center safety and efficacy analysis","volume":"13","author":"Kroeze","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111330_b0085","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","article-title":"Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design","volume":"17","author":"Chaft","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0090","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/JTO.0b013e318257fc1d","article-title":"Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib","volume":"7","author":"Pop","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0095","article-title":"Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma","volume":"27","author":"Amirault","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.radonc.2025.111330_b0100","article-title":"Palliative radiotherapy","volume":"360","author":"Spencer","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2025.111330_b0105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/mp.16274","article-title":"Modeling clinical outcomes in radiotherapy: NTCP, TCP and the \u201cTECs\u201d","volume":"50","author":"Yorke","year":"2023","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/COC.0000000000000501","article-title":"Concurrent radiation and immunotherapy: survey of practice patterns in the United States","volume":"42","author":"Amin","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0115","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1038\/s41598-021-86863-2","article-title":"Evaluation of practical experiences of German speaking radiation oncologists in combining radiation therapy with checkpoint blockade","volume":"11","author":"Kraus","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2025.111330_b0120","article-title":"ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors","author":"van Aken","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.radonc.2025.111330_b0130","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinids\/18.3.421","article-title":"Purpose of quality standards for infectious diseases. infectious diseases society of america","volume":"18","author":"Gross","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.radonc.2025.111330_b0135","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"key":"10.1016\/j.radonc.2025.111330_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.techfore.2020.120484","article-title":"Consensus in the delphi method: what makes a decision change?","volume":"163","author":"Barrios","year":"2021","journal-title":"Technol Forecast Soc Chang"},{"key":"10.1016\/j.radonc.2025.111330_b0145","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2025.111330_b0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccell.2018.03.023","article-title":"CDK4\/6 Inhibitors: the mechanism of action may not be as simple as once thought","volume":"34","author":"Klein","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.radonc.2025.111330_b0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2018.07.010","article-title":"Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response","volume":"102","author":"Huang","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40360-024-00770-6","article-title":"Comparative analysis of adverse events associated with CDK4\/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study","volume":"25","author":"Lin","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.radonc.2025.111330_b0165","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-020-0957-9","article-title":"Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature","volume":"123","author":"Beddok","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0170","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.adro.2019.03.011","article-title":"Safety and efficacy of palbociclib and radiation therapy in patients with metastatic breast cancer: initial results of a novel combination","volume":"4","author":"Chowdhary","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0175","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11060-019-03260-6","article-title":"CDK 4\/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases","volume":"144","author":"Figura","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2025.111330_b0180","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.breast.2019.05.001","article-title":"Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: preliminary assessment of toxicity","volume":"46","author":"Ippolito","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2025.111330_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2018.08.096","article-title":"Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer","volume":"42","author":"Meattini","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2025.111330_b0190","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.clbc.2020.05.013","article-title":"Cyclin-dependent kinase 4\/6 inhibitors combined with radiotherapy for patients with metastatic breast cancer","volume":"20","author":"Ratosa","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.radonc.2017.09.010","article-title":"Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients","volume":"126","author":"Hans","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030690","article-title":"Safety and feasibility of radiation therapy combined with CDK 4\/6 inhibitors in the management of advanced breast cancer","volume":"15","author":"Kubeczko","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111330_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12052044","article-title":"Efficacy of CDK 4\/6 inhibitors and radiotherapy in breast cancer patients with brain metastases","volume":"12","author":"Kubeczko","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.radonc.2025.111330_b0210","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.radonc.2022.10.023","article-title":"Safety of CDK4\/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer","volume":"177","author":"Visani","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0215","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijrobp.2022.07.005","article-title":"Radiation therapy with cyclin-dependent kinase 4\/6 inhibitors: a multi-institutional safety and toxicity study","volume":"114","author":"Al-Rashdan","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0220","first-page":"19","article-title":"Does concurrent use of CDK4\/6 inhibitors during palliative radiotherapy increase toxicity in patients with metastatic breast cancer?","volume":"19","author":"Howlett","year":"2020","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0225","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.rpor.2019.03.001","article-title":"Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: a case report","volume":"24","author":"Messer","year":"2019","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.radonc.2025.111330_b0230","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1038\/s41598-020-70430-2","article-title":"A single-center retrospective safety analysis of cyclin-dependent kinase 4\/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients","volume":"10","author":"Guerini","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2025.111330_b0235","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.21873\/anticanres.14534","article-title":"Severe gastrointestinal mucositis following concurrent palbociclib and palliative radiation therapy","volume":"40","author":"Nasir","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0240","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/jmrs.435","article-title":"Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature","volume":"68","author":"Dasgupta","year":"2021","journal-title":"J Med Radiat Sci"},{"key":"10.1016\/j.radonc.2025.111330_b0245","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.radonc.2018.09.020","article-title":"Severe acute radiation-induced enterocolitis after combined palbociclib and palliative radiotherapy treatment","volume":"131","author":"Kawamoto","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0250","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.radonc.2025.111330_b0255","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/annonc\/12.suppl_1.S35","article-title":"Mechanism of action of anti-HER2 monoclonal antibodies","volume":"12","author":"Baselga","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0260","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10549-014-3250-x","article-title":"HER2-family signalling mechanisms, clinical implications and targeting in breast cancer","volume":"149","author":"Elster","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.radonc.2025.111330_b0265","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0270","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","article-title":"Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III Trial N9831","volume":"27","author":"Halyard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0275","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10549-014-3166-5","article-title":"Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study","volume":"148","author":"Jacob","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.radonc.2025.111330_b0280","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2010.08.013","article-title":"The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study","volume":"47","author":"Caussa","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0285","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/annonc\/mdn029","article-title":"Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study","volume":"19","author":"Belkacemi","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0290","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijrobp.2010.06.057","article-title":"Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients","volume":"81","author":"Chargari","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0295","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.canrad.2016.10.002","article-title":"Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and\/or metastatic breast cancer: Assessment of early toxicity","volume":"21","author":"Ajgal","year":"2017","journal-title":"Cancer Radiotherapie"},{"key":"10.1016\/j.radonc.2025.111330_b0300","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/tbj.13421","article-title":"The efficacy and safety of hypofractionated radiotherapy with concurrent anti-HER-2 therapy following breast-conserving therapy for breast cancer","volume":"25","author":"Dreyfuss","year":"2019","journal-title":"Breast J"},{"key":"10.1016\/j.radonc.2025.111330_b0305","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.ijrobp.2009.03.027","article-title":"Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial","volume":"76","author":"Horton","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0310","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.coc.0000182440.11653.5f","article-title":"Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer","volume":"28","author":"Koukourakis","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0315","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s12032-014-0891-x","article-title":"Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series","volume":"31","author":"Meattini","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0320","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3389\/fonc.2019.00970","article-title":"Acute cardiotoxicity with concurrent trastuzumab and hypofractionated radiation therapy in breast cancer patients","volume":"9","author":"Sayan","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0325","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170822","article-title":"Use of helical tomotherapy in locally advanced and\/or metastatic breast cancer for locoregional treatment","volume":"91","author":"Thery","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2025.111330_b0330","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1186\/1471-2407-14-711","article-title":"Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy","volume":"14","author":"De Langhe","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0335","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1016\/j.clbc.2017.08.011","article-title":"Trastuzumab and hypofractionated whole breast radiotherapy: a victorious combination?","volume":"18","author":"De Santis","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0340","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clon.2015.04.033","article-title":"A prospective randomised Phase III clinical trial testing the role of prophylactic cranial radiotherapy in patients treated with trastuzumab for metastatic breast cancer - anglo celtic VII","volume":"27","author":"Canney","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2025.111330_b0345","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/cncr.30616","article-title":"Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies","volume":"123","author":"Miller","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0350","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ijrobp.2006.08.076","article-title":"Phase I\/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma","volume":"67","author":"Safran","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0355","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1081\/CNV-200032951","article-title":"Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study","volume":"22","author":"Safran","year":"2004","journal-title":"Cancer Invest"},{"key":"10.1016\/j.radonc.2025.111330_b0360","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/JCO.19.01814","article-title":"Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: TRAP study","volume":"38","author":"Stroes","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0365","doi-asserted-by":"crossref","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","article-title":"Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines","volume":"21","author":"Bovelli","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0370","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.2016.69.8480","article-title":"Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures","volume":"35","author":"van den Bogaard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0375","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2009.09.064","article-title":"Radiation-related heart disease: current knowledge and future prospects","volume":"76","author":"Darby","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0380","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","article-title":"HER2+ breast cancer treatment and cardiotoxicity: monitoring and management","volume":"177","author":"Jerusalem","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.radonc.2025.111330_b0385","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2478\/raon-2018-0011","article-title":"Early cardiotoxicity after adjuvant concomitant treatment with radiotherapy and trastuzumab in patients with breast cancer","volume":"52","author":"Marinko","year":"2018","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0390","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.18632\/oncotarget.6053","article-title":"Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab","volume":"7","author":"Cao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2025.111330_b0395","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijrobp.2016.12.018","article-title":"A phase 1\/2 trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation after transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer (Trial NRG Oncology RTOG 0524)","volume":"97","author":"Michaelson","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0400","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.radonc.2025.111330_b0405","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.radonc.2025.111330_b0410","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0415","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.radonc.2025.111330_b0420","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ijrobp.2008.07.031","article-title":"Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential","volume":"72","author":"Dungey","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0425","article-title":"Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data","volume":"43","author":"Friedlander","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.radonc.2025.111330_b0430","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2017.77.2665","article-title":"Concurrent veliparib with chest wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: the TBCRC 024 Phase I multicenter study","volume":"36","author":"Jagsi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0435","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-18-0467","article-title":"Final report of a phase i trial of olaparib with cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer","volume":"24","author":"Karam","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0440","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/neuonc\/noab111","article-title":"A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study","volume":"23","author":"Sim","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0445","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/neuonc\/noaa016","article-title":"A phase I\/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study","volume":"22","author":"Baxter","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0450","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1158\/1078-0432.CCR-18-0110","article-title":"Phase II study of iniparib with concurrent chemoradiation in patients with newly diagnosed glioblastoma","volume":"25","author":"Blakeley","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0455","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrclinonc.2013.177","article-title":"Appraising iniparib, the PARP inhibitor that never was\u2013what must we learn?","volume":"10","author":"Mateo","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0460","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1158\/1078-0432.CCR-11-2890","article-title":"Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro","volume":"18","author":"Patel","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0465","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/1078-0432.CCR-11-1973","article-title":"Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor","volume":"18","author":"Liu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0470","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11060-016-2275-x","article-title":"Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study","volume":"131","author":"Chabot","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2025.111330_b0475","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-015-1733-1","article-title":"Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study","volume":"122","author":"Mehta","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2025.111330_b0480","article-title":"Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma","volume":"44","author":"Navran","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0485","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cllc.2021.02.009","article-title":"A dose-finding study followed by a phase ii randomized, placebo-controlled trial of chemoradiotherapy with or without veliparib in stage iii non-small-cell lung cancer: SWOG 1206 (8811)","volume":"22","author":"Argiris","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0490","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2021.06.028","article-title":"Veliparib in combination with carboplatin\/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer","volume":"159","author":"Kozono","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0495","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/ijc.33737","article-title":"Combination of Olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP phase I trial","volume":"149","author":"Loap","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0500","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijrobp.2020.09.032","article-title":"Combination of olaparib and radiation therapy for triple negative breast cancer: preliminary results of the RADIOPARP phase 1 trial","volume":"109","author":"Loap","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0505","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial","author":"Loap","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0510","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ygyno.2017.01.016","volume":"144","author":"Reiss","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0515","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2468-1253(17)30012-2","article-title":"Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study","volume":"2","author":"Czito","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.radonc.2025.111330_b0520","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ebiom.2018.12.060","article-title":"A phase 1 study of veliparib, a PARP-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer","volume":"40","author":"Tuli","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.radonc.2025.111330_b0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11033-021-06607-3","article-title":"The PI3K\/AKT\/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines","volume":"48","author":"Mardanshahi","year":"2021","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.radonc.2025.111330_b0530","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.radonc.2025.111330_b0535","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1667\/RR2323.1","article-title":"The mTOR inhibitor rapamycin suppresses DNA double-strand break repair","volume":"175","author":"Chen","year":"2011","journal-title":"Radiat Res"},{"key":"10.1016\/j.radonc.2025.111330_b0540","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1038\/sj.onc.1208715","article-title":"Enhanced radiation damage of tumor vasculature by mTOR inhibitors","volume":"24","author":"Shinohara","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2025.111330_b0545","unstructured":"Eshleman JS, Carlson BL, Mladek AC, Kastner BD, L. SK, N. SJ. Inhibition of the Mammalian Target of Rapamycin Sensitizes U87 Xenografts to Fractionated Radiation Therapy. Cancer Res. 2002;62(24):7291-7."},{"key":"10.1016\/j.radonc.2025.111330_b0550","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","article-title":"Common toxicities of mammalian target of rapamycin inhibitors","volume":"6","author":"Soefje","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0555","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdv105","article-title":"Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer","volume":"26","author":"Deutsch","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0560","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2015.07.039","article-title":"A phase I-II study on the combination of rapamycin and short course radiotherapy in rectal cancer","volume":"116","author":"Buijsen","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0565","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1158\/1078-0432.CCR-14-2424","article-title":"Higher risk of infections with PI3K-AKT-mTOR pathway inhibitors in patients with advanced solid tumors on Phase I clinical trials","volume":"21","author":"Rafii","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0570","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/TP.0b013e3182551021","article-title":"Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature","volume":"94","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.radonc.2025.111330_b0575","article-title":"A dose-finding and biomarker evaluation phase ib study of everolimus in association with 5-fluorouracil and pelvic radiotherapy as neoadjuvant treatment of locally advanced rectal cancer (E-LARC Study)","volume":"16","author":"Gelsomino","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0580","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1158\/1078-0432.CCR-10-1453","article-title":"Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks","volume":"16","author":"Sarkaria","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0585","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijrobp.2016.10.013","article-title":"Phase 1 trial of everolimus and radiation therapy for salvage treatment of biochemical recurrence in prostate cancer patients following prostatectomy","volume":"97","author":"Narayan","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0590","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/BLC-160090","article-title":"Phase I clinical trial of everolimus combined with trimodality therapy in patients with muscle-invasive bladder cancer","volume":"3","author":"Bachir","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0595","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00280-016-3064-0","article-title":"A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I","volume":"78","author":"de Melo","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.radonc.2025.111330_b0600","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3109\/0284186X.2014.923583","article-title":"Incidence and risk of rash to mTOR inhibitors in cancer patients\u2013a meta-analysis of randomized controlled trials","volume":"54","author":"Shameem","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0605","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.oraloncology.2016.08.008","article-title":"m-TOR inhibitor as potential radiosensitizer for head and neck squamous cell carcinoma: a case report of an organ transplant patient and review of the literature","volume":"62","author":"Daste","year":"2016","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0610","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ijrobp.2013.04.036","article-title":"RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma","volume":"86","author":"Chinnaiyan","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0615","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/neuonc\/nox209","article-title":"A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913","volume":"20","author":"Chinnaiyan","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0620","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","article-title":"Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)","volume":"22","author":"Wick","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0625","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/neuonc\/nou328","article-title":"A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K","volume":"17","author":"Ma","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0630","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/neuonc\/nov083","article-title":"Phase I dose-escalation study of the PI3K\/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma","volume":"17","author":"Wen","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0635","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijrobp.2010.05.064","article-title":"North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme","volume":"81","author":"Sarkaria","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0640","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1007\/s10637-011-9775-5","article-title":"A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study","volume":"30","author":"Mason","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.radonc.2025.111330_b0645","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1002\/cncr.28142","article-title":"A prospective, phase 1\/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor","volume":"119","author":"Chan","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0650","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/COC.0b013e31827b45d4","article-title":"Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675","volume":"37","author":"Dronca","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0655","article-title":"Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases","volume":"1\u20139","author":"Juloori","year":"2019","journal-title":"J Neurosurg"},{"key":"10.1016\/j.radonc.2025.111330_b0660","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijrobp.2013.06.2043","article-title":"A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer","volume":"87","author":"Fury","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0665","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/hed.20898","article-title":"Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck","volume":"31","author":"Shinohara","year":"2009","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2025.111330_b0670","first-page":"5511","article-title":"Early and severe radiation toxicity associated with concurrent sirolimus in an organ transplant recipient with head and neck cutaneous squamous cell carcinoma: a case report","volume":"35","author":"Manyam","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0675","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/CAD.0000000000000352","article-title":"Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient","volume":"27","author":"Bonetta","year":"2016","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.radonc.2025.111330_b0680","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/COC.0000000000000524","article-title":"Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer","volume":"42","author":"Saba","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0685","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/JTO.0b013e3180cc2587","article-title":"Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer","volume":"2","author":"Sarkaria","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0690","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cllc.2013.11.007","article-title":"A phase I study of temsirolimus and thoracic radiation in non\u2013small-cell lung cancer","volume":"15","author":"Waqar","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2025.111330_b0695","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1200\/JCO.2013.50.1643","article-title":"Early and severe radiation esophagitis associated with concurrent sirolimus","volume":"34","author":"Akthar","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0700","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000353309","article-title":"Radiation-induced esophagitis exacerbated by everolimus","volume":"6","author":"Miura","year":"2013","journal-title":"Case Reports Oncology"},{"key":"10.1016\/j.radonc.2025.111330_b0705","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000535","article-title":"Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study","volume":"4","author":"Dengina","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.radonc.2025.111330_b0710","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3171\/2019.9.SPINE19377","article-title":"Spine radiosurgery in adolescents and young adults: Early outcomes and toxicity in patients with metastatic Ewing sarcoma and osteosarcoma","volume":"32","author":"Parsai","year":"2020","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.radonc.2025.111330_b0715","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.12998\/wjcc.v8.i13.2758","article-title":"Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation","volume":"8","author":"Au","year":"2020","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.radonc.2025.111330_b0720","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijrobp.2011.06.1985","article-title":"Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery","volume":"83","author":"Pinnix","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0725","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s10637-010-9613-1","article-title":"Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy","volume":"30","author":"Kirova","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.radonc.2025.111330_b0730","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.brachy.2018.06.001","article-title":"Low-dose-rate brachytherapy for prostate cancer in renal transplant recipients","volume":"17","author":"Rivero-Belenchon","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111330_b0735","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.radonc.2025.111330_b0740","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111330_b0745","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbmt.2015.08.036","article-title":"Nonmyeloablative stem cell transplantation with alemtuzumab\/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease","volume":"22","author":"Saraf","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.radonc.2025.111330_b0750","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijrobp.2008.04.071","article-title":"Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation","volume":"73","author":"Wong","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111330_b0755","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S1470-2045(23)00534-X","article-title":"International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: european society for radiotherapy and oncology (ESTRO)-endorsed recommendations","volume":"25","author":"Meattini","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0760","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0765","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-18-2466","article-title":"Clinical development of novel drug-radiotherapy combinations","volume":"25","author":"Ahmad","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.111330_b0770","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrclinonc.2016.79","article-title":"Clinical development of new drug-radiotherapy combinations","volume":"13","author":"Sharma","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111330_b0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110060","article-title":"Essential requirements for reporting radiation therapy in breast cancer clinical trials: an international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)","volume":"195","author":"Kaidar-Person","year":"2024","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025053344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025053344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:39:13Z","timestamp":1770269953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025053344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":155,"alternative-id":["S0167814025053344"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111330","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4\/6, HER2, PARP, or mTOR inhibitors","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111330"}}